C
Cardiff Oncology D
D
CRDF
3.65000
USD
0.06
(1.67%)
مغلق
حجم التداول
20,975
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
242,819,367
الأخبار المقالات
العنوان: Cardiff Oncology
القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.